HIC2 controls developmental hemoglobin switching by repressing BCL11A transcription

Area of Science:

• Molecular Biology
• Developmental Biology
• Genetics

Background:

• The switch from fetal to adult hemoglobin production is a key developmental process.
• BCL11A transcription factor is critical for repressing fetal globin genes in adults, but its regulation is not fully understood.
• Understanding this switch is vital for treating hemoglobinopathies like sickle cell disease and thalassemia.

Purpose of the Study:

• To identify novel regulators of BCL11A transcription during the fetal-to-adult hemoglobin switch.
• To elucidate the mechanism by which HIC2 controls BCL11A expression.
• To explore the therapeutic potential of targeting HIC2 for hemoglobinopathies.

Main Methods:

• Identified HIC2 as a repressor of BCL11A transcription through gene expression studies.
• Investigated the reciprocal expression patterns of HIC2 and BCL11A during erythroid development.
• Utilized chromatin immunoprecipitation and DNA-binding assays to study HIC2-enhancer interactions.
• Employed crystallography to determine the structural basis of HIC2-GATA1 interaction.
• Performed functional assays by overexpressing HIC2 in adult erythroid cells and assessing HBG expression.

Main Results:

• HIC2 acts as a transcriptional repressor of BCL11A.
• HIC2 and BCL11A exhibit reciprocal expression during development.
• HIC2 binds to BCL11A enhancers, reducing chromatin accessibility and GATA1 binding.
• Crystallography revealed steric hindrance as a mechanism for HIC2 inhibiting GATA1 binding.
• Loss of HIC2 in fetal cells increases BCL11A transcription and decreases HBG expression.

Conclusions:

• HIC2 is a key regulator of the fetal-to-adult hemoglobin switch by controlling BCL11A transcription.
• HIC2 functions by modulating enhancer accessibility and transcription factor binding.
• HIC2 represents a conserved mechanism for developmental gene regulation with therapeutic implications for hemoglobinopathies.